Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Methods Mol Biol. 2020;2055:23–60. doi: 10.1007/978-1-4939-9773-2_2

Table 3.

Development progress of TIGIT inhibitors

Product Company and
partner
(if applicable)		 Structure TIGIT
target		 Phase of development ORR
MK-7684 Merck Fully humanized, IgG1 CD155/CD112 Phase I dose-escalation and dose-expansion in PD-1 naïve and refractory tumors (select malignancies) (NCT02964013) Monotherapy: 1/34 (3%) Combination with
pembrolizumab: 8/34 (19%)
BMS-986207 Bristol Myers Squibb Fully humanized, IgG1 with inert Fc CD155/CD112 Phase I dose-escalation and dose-expansion in PD-1 refractory tumors (select malignancies) (NCT02913313) Unreported
CGEN-15137/COM902 Compugen Unknown TIGIT Unreported Unreported
CGEN-15207/COM701 Compugen Unknown PVR Unreported Unreported
MTIG7192A Genentech Unknown TIGIT Phase I dose-escalation and dose-expansion in PD-1 refractory tumors (select malignancies) (NCT02794571) Unreported
Unknown TIGIT Randomized phase II study of MTIG7192A/atezolizumab vs. placebo/atezolizumab in PD-1/chemotherapy naïve metastatic NSCLC (NCT03563716) Unreported
SP 8374/PTZ-201 Astellas Unknown TIGIT Unreported Unreported